Por favor, use este identificador para citar o enlazar este ítem:
https://repositorio.uca.edu.ar/handle/123456789/14304
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Pérez Lloret, Santiago | es |
dc.contributor.author | Peralta, María Cecilia | es |
dc.contributor.author | Barrantes, Francisco José | es |
dc.date.accessioned | 2022-06-29T12:16:36Z | - |
dc.date.available | 2022-06-29T12:16:36Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | Pérez Lloret, S., Peralta, M.C., Barrantes, F.J. Pharmacotherapies for parkinson's disease symptoms related to cholinergic degeneration [en línea]. Expert Opinion on Pharmacotherapy. 2016, 17(18) doi:10.1080/14656566.2016.1254189 Disponible en: https://repositorio.uca.edu.ar/handle/123456789/14304 | es |
dc.identifier.issn | 1465-6566 | - |
dc.identifier.issn | 1744-7666 (online) | - |
dc.identifier.uri | https://repositorio.uca.edu.ar/handle/123456789/14304 | - |
dc.description.abstract | Abstract: Dopamine depletion is one of the most important features of Parkinson's Disease (PD). However, insufficient response to dopaminergic replacement therapy suggests the involvement of other neurotransmitter systems in the pathophysiology of PD. Cholinergic degeneration contributes to gait impairments, cognitive impairment, psychosis, and REM-sleep disturbances, among other symptoms. Areas covered: In this review, we explore the idea that enhancing cholinergic tone by pharmacological or neurosurgical procedures could be a first-line therapeutic strategy for the treatment of symptoms derived from cholinergic degeneration in PD. Expert opinion: Rivastigmine, a drug that increases cholinergic tone by inhibiting the enzyme cholinesterase, is effective for dementia, whereas the use of Donepezil is still in the realm of investigation. Interesting results suggest the efficacy of these drugs in the treatment of gait dysfunction. Evidence on the clinical effects of these drugs for psychosis and REM-sleep disturbances is still weak. Stimulation of the pedunculo-pontine tegmental nuclei (which provide cholinergic innervation to the brain stem and subcortical nuclei) has also been used with some success for the treatment of gait dysfunction. Anticholinergic drugs should be used with caution in PD, as they may aggravate cholinergic symptoms. Notwithstanding, in some patients they might help control parkinsonian motor symptoms. | es |
dc.format | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | Taylor & Francis | es |
dc.rights | info:eu-repo/semantics/closedAccess | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.source | Expert Opinion on Pharmacotherapy. 2016, 17(18) | es |
dc.subject | TRATAMIENTO MEDICO | es |
dc.subject | ENFERMEDAD DE PARKINSON | es |
dc.subject | NEURODEGENERACION | es |
dc.subject | DETERIORO COGNITIVO | es |
dc.subject | DEMENCIA | es |
dc.title | Pharmacotherapies for parkinson's disease symptoms related to cholinergic degeneration | es |
dc.type | Artículo | es |
dc.identifier.doi | 10.1080/14656566.2016.1254189 | - |
dc.identifier.pmid | 27785919 | - |
uca.disciplina | MEDICINA | es |
uca.issnrd | 1 | es |
uca.affiliation | Fil: Pérez Lloret, Santiago. Universidad de Buenos Aires. Instituto de Investigación Cardiológica; Argentina | es |
uca.affiliation | Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Ténicas; Argentina | es |
uca.affiliation | Fil: Peralta, María Cecilia. Hospital Universitario CEMIC; Argentina | es |
uca.affiliation | Fil: Barrantes, Francisco José. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas. Laboratorio de Neurobiología Molecular; Argentina | es |
uca.affiliation | Fil: Barrantes, Francisco José. Consejo Nacional de Investigaciones Científicas y Ténicas; Argentina | es |
uca.version | publishedVersion | es |
item.grantfulltext | mixedopen | - |
item.languageiso639-1 | en | - |
item.fulltext | With Fulltext | - |
crisitem.author.dept | Laboratorio de Neurobiología Molecular | - |
crisitem.author.dept | Consejo Nacional de Investigaciones Científicas y Técnicas | - |
crisitem.author.dept | Instituto de Investigaciones Biomédicas - BIOMED | - |
crisitem.author.dept | Laboratorio de Neurobiología Molecular | - |
crisitem.author.dept | Facultad de Ciencias Médicas | - |
crisitem.author.orcid | 0000-0001-9069-6512 | - |
crisitem.author.orcid | 0000-0002-4745-681X | - |
crisitem.author.parentorg | Instituto de Investigaciones Biomédicas - BIOMED | - |
crisitem.author.parentorg | Facultad de Ciencias Médicas | - |
crisitem.author.parentorg | Instituto de Investigaciones Biomédicas - BIOMED | - |
crisitem.author.parentorg | Pontificia Universidad Católica Argentina | - |
Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | Usuarios registrados haga click en: Login |
---|---|---|---|---|
pharmacotherapies-for-parkinson.pdf | 1,08 MB | Adobe PDF | ||
thumb.pdf | 160,41 kB | Adobe PDF | ![]() Visualizar/Abrir |
Visualizaciones de página(s)
84
comprobado en 27-abr-2024
Descarga(s)
21
comprobado en 27-abr-2024
Google ScholarTM
Consultar
Altmetric
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons